AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.



Biotechnology

AC Immune

Andrea Pfeifer

Christopher R.

Madiha Derouazi

Nuno Mendonça

Bojana Portmann

Julien Rongère

Alexandre Caratsch

Marie Kosco-Vilbois

Piergiorgio Donati

Christopher Roberts

Jean-Fabien Monin

Howard Donovan

The executive team of AC Immune has experience in a variety of fields related to immunology. The CSO previously worked at NovImmune, and the Head of Immunology Department has worked at Serono SA and Glaxo Wellcome Research Institute. The team is also educated in a variety of disciplines related to immunology, including biology and anatomy/immunology.

CEO and Executive Team

Board of Directors

Leadership Team

CEO and Executive Team

About

Team members

Other teams at AC Immune

Board of Directors

Leadership Team